echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Xinlitai: the model of drug exchange affects the performance in the second half of the year

    Xinlitai: the model of drug exchange affects the performance in the second half of the year

    • Last Update: 2014-07-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: a senior executive of big wisdom astak news agency said at a strategic meeting organized by a securities firm on July 25, 2014 that the old trading platform in Guangdong had been closed in May, which had a certain impact on the sales of the company's main product "Taijia" (clopidogrel tablets) in the second half of the year after the drug exchange went online, but still maintained a 20% - 30% growth in sales revenue throughout the year According to statistics, shuaixin, a rising star of Lepu medical (300003 SZ) products, has successively encroached on the market share of xinlitai in Beijing, Qinghai, Guangdong, Shandong and other places by virtue of its price advantage Especially in Guangdong, all markets are occupied by Lepu medical In response, the aforementioned executives said that "Taijia" mainly aims at the secondary and tertiary markets, while Lepu medical's "shuaixin" is positioned at the grassroots market In Guangdong, because the old trading platform was still in operation before May, the actual sales of "Taijia" still existed, which had little impact on the company's first half performance In May, the old trading platform was closed, "more or less in the second half of the year, but as for the impact, we will show it in the pre disclosure of the third quarter report." Guangdong Pharmaceutical exchange has replaced the old purchase and trading platform in May, completed five rounds of base drug transactions, and officially ascended the post Industry insiders pointed out that at present, many enterprises (including foreign-funded enterprises and domestic high-quality generic pharmaceutical enterprises) have complaints, on the grounds that the policies of Guangdong drug exchange are contrary to the national policies, "quality first, reasonable price, priority to purchase generic drugs reaching international level" and other principles are not reflected, and subsequent policies may be loose.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.